Oleg Gligich
Publications by Year
Research Areas
Economic and Financial Impacts of Cancer, Health Systems, Economic Evaluations, Quality of Life, Glioma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment
Most-Cited Works
- → Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma(2022)373 cited
- → Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.(2023)5 cited
- → CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL(2022)4 cited
- → Ethnic disparities in clinical trials for FDA-approved drugs in prostate cancer: A post–COVID-19 era analysis (2020-2024).(2025)
- → QIM26-311: Implementation of a Dual Escalation Protocol to Reduce New-Patient Wait Times in Oncology and Malignant Hematology: A Quality Improvement Initiative at Mount Sinai Comprehensive Cancer Center(2026)
- → Ethnic disparities in clinical trials for FDA-approved drugs in colon cancer: A post-COVID era analysis (2020-2024).(2025)
- → Prevalence and clinical impact of actionable genomic alterations in non–clear cell renal cell carcinoma: A review of NGS-based trials and real-world data.(2026)
- → Ethnic disparities in clinical trials for FDA-approved drugs in lung cancer: A post-COVID era analysis (2020-2024).(2025)
- → Ethnic disparities in clinical trials for FDA-approved drugs in renal cell carcinoma: An analysis in the post-COVID-19-era (2020-2024).(2025)
- → Ethnic disparities in clinical trials for FDA-approved drugs in breast cancer: A post-COVID era analysis (2020-2024).(2025)